drugset / Trial / NCT00516100
Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC
Phase 1/2
Unknown
62 enrolled
Aptium Oncology Research Network
Millennium Pharmaceuticals, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Pemetrexed is an FDA-approved treatment for advanced lung cancer but the response rate is still very low. Bortezomib is currently approved to treat myeloma in patients who have already been treated. Currently, multiple studies are actively investigating how well bortezomib works with other drugs. This study is testing how much bortezomib can be given to advanced lung cancer patients who have already received one treatment. This study will also see how well bortezomib and pemetrexed work together to treat lung cancer patients.
Timeline
- Start
- 2006-01
- Primary completion
- 2010-01
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | — |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | — |